Medication info
Posidime Sustained-Release Tablet 10/1000 mg

Posidime Sustained-Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped film-coated tablet with a convex shape on both sides
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202107224 · Approved 2021.10.29 · Insurance code 643705360

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior experience of antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2, with no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This drug helps improve blood sugar control in adult patients with type 2 diabetes through the combined administration of dapagliflozin and metformin. It is particularly effective as an adjunctive treatment in conjunction with dietary and exercise therapies. Furthermore, caution is advised when using in patients with type 2 diabetes who have cardiovascular disease or risk factors, where blood sugar is not sufficiently controlled. For related clinical trial information, please refer to guidance for healthcare professionals. This medication is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior experience of antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin the patient was taking or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering drugs. Because this may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and below 60 mL/min/1.73 m2, with no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Precautions

This medication is used for the treatment of diabetes and may rarely cause a serious metabolic complication called lactic acidosis in some patients. Lactic acidosis is a condition where acidity in the body increases abnormally, which can be life-threatening if severe. When taking this medication with insulin or sulfonylureas, there is a risk of hypoglycemia, so blood sugar levels should be closely monitored. Patients with severely impaired kidney function, dehydration, serious infections, or acute conditions that may affect kidney function, such as acute myocardial infarction, should not take this medication. In addition, pregnant or potentially pregnant women, nursing mothers, and patients undergoing dialysis should not use this medication. Patients at risk of dehydration or hypotension should evaluate their hydration status and kidney function before taking this medication and continuously monitor for symptoms of hypotension and kidney function during treatment. This medication may increase the risk of genital or urinary tract infections, so if symptoms of infection occur, immediate consultation with a healthcare professional is necessary. Vitamin B12 levels can decrease, thus it is advisable to check vitamin B12 status during long-term use. Excessive alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. Patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume once kidney function is confirmed to be normal post-surgery. If symptoms such as sudden fatigue, muscle pain, shortness of breath, or abdominal pain arise during treatment, inform the doctor immediately, as serious conditions like lactic acidosis or ketoacidosis may be suspected. Elderly patients or those with impaired kidney function should have their dosages adjusted, and regular kidney function tests are required. In the event of overdose, immediate medical attention is necessary, and prompt treatment should be undertaken. This medication does not significantly impair driving or machine operation, but caution should be exercised due to possible symptoms such as dizziness. Store this medication out of reach of children and keep it in its original container to prevent misuse and degradation of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 82 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • elevated blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius. This will help preserve the effectiveness of the medication for a longer duration.

Appearance and packaging

Appearance

Yellow, oval-shaped film-coated tablet with a convex shape on both sides

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.